报告人：Dr. Kaixin Zhou，School of Medicine, University of Dundee, UK

主持人：徐涛 研究员

报告时间：10月12日上午10点

报告地点：6号楼十层会议室

报告摘要：

Metformin is the first line antidiabetic agent used by more than 120 million patients with type 2 diabetes worldwide. Despite the clinical success of this agent for over 50 years, its exact mechanism of glucose lowering remains elusive. Until recently it was also unclear how much genetic variants have contributed to the variation in how individual patient responded to metformin. Using Electronic Medical Record (EMR) linked GWAS data, we established that glycaemic response to metformin has a similar genetic architecture as type 2 diabetes, in that multiple variants with small to moderate impacts together explaining about 30% of the variance. Using the multiple stage GWAS-replication strategy, we further led the discovery of the only two known metformin response variants to date. These two variants are not only informative to better understanding the drug action biology, but also potential biomarkers for precision medicine in type 2 diabetes.